Kyung Han Kim, Yang-Hyun Baek, Yeo Wool Kang, Byeol-A Yoon, Sang Yi Moon
{"title":"阿替佐利珠单抗治疗晚期肝细胞癌后并发横贯性脊髓炎一例。","authors":"Kyung Han Kim, Yang-Hyun Baek, Yeo Wool Kang, Byeol-A Yoon, Sang Yi Moon","doi":"10.4166/kjg.2023.054","DOIUrl":null,"url":null,"abstract":"<p><p>The results of the IMbrave150 study have led to widespread use of the combination therapy of atezolizumab and bevacizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma (HCC). Compared to traditional cytotoxic chemotherapy agents, immune checkpoint inhibitors show a spectrum of side effects ranging from mild side effects such as skin rash to potentially severe systemic effects such as myocarditis. We present a case of transverse myelitis diagnosed during the treatment of HCC with atezolizumab and bevacizumab combination therapy.</p>","PeriodicalId":22736,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":"82 1","pages":"35-39"},"PeriodicalIF":0.6000,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Case of Transverse Myelitis Following Treatment with Atezolizumab for Advanced Hepatocellular Carcinoma.\",\"authors\":\"Kyung Han Kim, Yang-Hyun Baek, Yeo Wool Kang, Byeol-A Yoon, Sang Yi Moon\",\"doi\":\"10.4166/kjg.2023.054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The results of the IMbrave150 study have led to widespread use of the combination therapy of atezolizumab and bevacizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma (HCC). Compared to traditional cytotoxic chemotherapy agents, immune checkpoint inhibitors show a spectrum of side effects ranging from mild side effects such as skin rash to potentially severe systemic effects such as myocarditis. We present a case of transverse myelitis diagnosed during the treatment of HCC with atezolizumab and bevacizumab combination therapy.</p>\",\"PeriodicalId\":22736,\"journal\":{\"name\":\"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi\",\"volume\":\"82 1\",\"pages\":\"35-39\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4166/kjg.2023.054\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4166/kjg.2023.054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
A Case of Transverse Myelitis Following Treatment with Atezolizumab for Advanced Hepatocellular Carcinoma.
The results of the IMbrave150 study have led to widespread use of the combination therapy of atezolizumab and bevacizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma (HCC). Compared to traditional cytotoxic chemotherapy agents, immune checkpoint inhibitors show a spectrum of side effects ranging from mild side effects such as skin rash to potentially severe systemic effects such as myocarditis. We present a case of transverse myelitis diagnosed during the treatment of HCC with atezolizumab and bevacizumab combination therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
